Celularity (NASDAQ:CELU) Trading 1.3% Higher After Analyst Upgrade

Key Points

• Celularity's stock price rose by 1.3% after an upgrade from Wall Street Zen, changing its rating from sell to hold.
• WBB Securities initiated coverage on Celularity with a moderate buy rating and a price target of $6.00.
• Institutional investors have increased their stakes significantly, with Bank of America Corp DE raising its holdings by 1,538.1% during the second quarter.

Celularity, Inc. (NASDAQ:CELU - Get Free Report) shares shot up 1.3% during mid-day trading on Monday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The company traded as high as $4.00 and last traded at $3.84. 36,127 shares changed hands during trading, a decline of 55% from the average session volume of 80,518 shares. The stock had previously closed at $3.79.

Separately, WBB Securities initiated coverage on shares of Celularity in a report on Monday, August 18th. They issued a "moderate buy" rating and a $6.00 price objective for the company.

Institutional Investors Weigh In On Celularity

Several hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd raised its holdings in Celularity by 106.4% during the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock worth $42,000 after buying an additional 11,057 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Celularity in the 1st quarter valued at about $34,000. Bank of America Corp DE increased its holdings in shares of Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock valued at $73,000 after purchasing an additional 35,023 shares during the period. Two Sigma Investments LP acquired a new position in shares of Celularity in the 4th quarter valued at about $93,000. Finally, Valmark Advisers Inc. bought a new stake in shares of Celularity in the 2nd quarter valued at approximately $98,000. 19.02% of the stock is currently owned by institutional investors.

Celularity Trading Up 1.3%

The firm has a market cap of $91.97 million, a P/E ratio of -1.45 and a beta of 0.79. The company has a 50 day moving average of $2.75 and a 200 day moving average of $2.10. The company has a debt-to-equity ratio of 4.07, a quick ratio of 0.28 and a current ratio of 0.38.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.